Veeva and IQVIA: A New Era of Collaboration in Clinical Trials
In a transformative move, Veeva Systems and IQVIA, two titans in the life sciences sector, have shifted from litigation...
Anavex Publishes Blarcamesine Autophagy Study Results
Anavex Life Sciences has published preclinical data in •iScience• further elucidating the mechanism by which its SIGMAR1 (S1R) agonist,...
Incannex Reports Positive Phase 2 Trial Results for Generalized Anxiety Disorder
Incannex Healthcare’s Phase 2 trial of PSX-001 (formerly Psi-GAD), a psilocybin-assisted therapy for generalized anxiety disorder (GAD), demonstrated statistically...
Marker Therapeutics Reports Encouraging Response Rates in Lymphoma Study
Marker Therapeutics’ Phase 1 APOLLO study of MT-601 in relapsed B-cell lymphoma patients yielded a 66% objective response rate...
Regeneron’s Phase 3 Trial Shows Positive Results in Myasthenia Gravis
Cemdisiran monotherapy, administered subcutaneously every three months, demonstrated a 2.3-point placebo-adjusted improvement in the Myasthenia Gravis Activities of Daily...
BioXcel Therapeutics Announces Topline Results from Phase 3 Trial of Igalmi
BioXcel Therapeutics’ BXCL501, a sublingual dexmedetomidine film, met its primary endpoint of tolerability in the SERENITY At-Home Phase 3...
Telitacicept Succeeds in Phase 3 IgA Nephropathy Trial
In Stage A of a Phase 3 trial in China, RemeGen’s telitacicept achieved a 55% reduction in 24-hour urine...
Life Biosciences Unveils New Data on Epigenetic Reprogramming at ARDD 2025
Life Biosciences’ preclinical data from the ARDD meeting showcase promising results for its Partial Epigenetic Reprogramming (PER) platform in...
Memgen Doses First Patient in Phase 1 Combination Trial for Advanced NSCLC
Memgen has dosed the first patient in a Phase 1 combination cohort evaluating its oncolytic immunotherapy MEM-288 alongside docetaxel...
PDS Biotech: Versatile-002 Trial Shows Final Topline Survival Data
In a Phase 2 trial (VERSATILE-002), PDS Biotechnology’s PDS0101, in combination with Keytruda, achieved a median overall survival (mOS)...